Sionna Therapeutics (NASDAQ:SION) Posts Earnings Results, Misses Estimates By $0.02 EPS

Sionna Therapeutics (NASDAQ:SION) released its earnings results on Thursday. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02), FiscalAI reports.

Sionna Therapeutics Trading Up 2.9%

NASDAQ SION traded up $1.43 during trading hours on Friday, hitting $51.04. The company’s stock had a trading volume of 746,247 shares, compared to its average volume of 603,064. The company has a market capitalization of $2.30 billion, a PE ratio of -23.41 and a beta of 1.33. Sionna Therapeutics has a 52 week low of $17.09 and a 52 week high of $54.97. The company’s 50-day simple moving average is $42.35 and its two-hundred day simple moving average is $40.41.

Insider Activity at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 85,918 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director directly owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 773,004 shares of company stock valued at $35,327,383. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SION. UBS Group AG grew its stake in Sionna Therapeutics by 91.1% in the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock valued at $3,669,000 after buying an additional 42,511 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Sionna Therapeutics by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after acquiring an additional 41,797 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Sionna Therapeutics by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after acquiring an additional 117,903 shares during the period. Candriam S.C.A. purchased a new position in shares of Sionna Therapeutics in the first quarter valued at $9,494,000. Finally, Eventide Asset Management LLC purchased a new position in shares of Sionna Therapeutics in the fourth quarter valued at $26,290,000.

Analysts Set New Price Targets

Several research firms have weighed in on SION. Citizens Jmp reaffirmed a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Wall Street Zen lowered Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday. Wedbush began coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.